Treatment of advanced melanoma has been improved considerably with the use of (i) targeted therapy, designed to target the most common oncogenic mutations (e.g., BRAF/MEK inhibitors); and (ii) immunotherapy, which aims at stimulating the anti-tumor immune response mainly by T-cell reactivation (e.g., immune checkpoint inhibitors)4,5. Here, BRAF is linked to neoplasm.